Your browser is no longer supported. Please, upgrade your browser.
Settings
CRL Charles River Laboratories International, Inc. daily Stock Chart
CRL [NYSE]
Charles River Laboratories International, Inc.
Index- P/E28.44 EPS (ttm)4.39 Insider Own1.10% Shs Outstand48.84M Perf Week-3.03%
Market Cap6.10B Forward P/E19.56 EPS next Y6.39 Insider Trans-19.99% Shs Float47.34M Perf Month-4.75%
Income213.90M PEG2.31 EPS next Q1.41 Inst Own99.10% Short Float2.98% Perf Quarter-5.53%
Sales2.14B P/S2.85 EPS this Y29.10% Inst Trans0.62% Short Ratio3.51 Perf Half Y6.58%
Book/sh25.94 P/B4.82 EPS next Y7.74% ROA4.00% Target Price142.27 Perf Year17.89%
Cash/sh2.95 P/C42.35 EPS next 5Y12.32% ROE11.80% 52W Range96.70 - 139.72 Perf YTD14.17%
Dividend- P/FCF18.99 EPS past 5Y14.70% ROI8.90% 52W High-10.56% Beta0.76
Dividend %- Quick Ratio1.30 Sales past 5Y10.50% Gross Margin36.50% 52W Low29.22% ATR4.34
Employees11800 Current Ratio1.60 Sales Q/Q26.10% Oper. Margin13.60% RSI (14)41.90 Volatility3.06% 3.15%
OptionableYes Debt/Eq1.34 EPS Q/Q12.80% Profit Margin6.40% Rel Volume0.68 Prev Close127.92
ShortableYes LT Debt/Eq1.32 EarningsNov 07 BMO Payout0.00% Avg Volume402.37K Price124.96
Recom2.10 SMA20-3.78% SMA50-1.79% SMA2005.76% Volume272,525 Change-2.31%
Dec-14-18Initiated Deutsche Bank Buy
Oct-09-18Initiated UBS Neutral
Aug-23-18Upgrade Raymond James Mkt Perform → Outperform
Jul-17-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-15-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
Feb-14-18Upgrade SunTrust Hold → Buy
Jan-22-18Downgrade SunTrust Buy → Hold
Jan-19-18Initiated Evercore ISI In-line $117
Dec-13-17Initiated Argus Buy $120
Sep-19-17Initiated RBC Capital Mkts Sector Perform $110
Dec-16-16Upgrade Goldman Sell → Neutral
Nov-30-16Upgrade Barclays Underweight → Equal Weight $65 → $77
Sep-06-16Downgrade UBS Neutral → Sell $83 → $78
Jun-21-16Initiated Credit Suisse Neutral $84
May-20-16Reiterated Barclays Underweight $60 → $65
Apr-26-16Initiated Gabelli & Co Buy $96
Jan-07-16Upgrade Wells Fargo Market Perform → Outperform
Oct-12-15Upgrade Wells Fargo Underperform → Market Perform
Jul-31-15Reiterated Deutsche Bank Hold $76 → $79
Jul-10-15Upgrade BofA/Merrill Neutral → Buy $76 → $83
Dec-15-18 11:35PM  Charles River Laboratories International Inc. (CRL): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-07-18 02:30PM  Calculating The Intrinsic Value Of Charles River Laboratories International Inc (NYSE:CRL) Simply Wall St.
08:00AM  Investor Expectations to Drive Momentum within Raytheon, S&P Global, Teledyne Technologies, Nordstrom, Charles River Laboratories International, and U.S. Silica Discovering Underlying Factors of Influence GlobeNewswire
Dec-06-18 08:25PM  Cramer's lightning round: Take a long-term view on JP Morgan's stock CNBC
Dec-03-18 09:30AM  SYNH vs. CRL: Which Stock Is the Better Value Option? Zacks
Nov-29-18 04:25PM  IBD 50 Stock Breaks Out Amid Boost For Medical Research Stocks Investor's Business Daily
Nov-27-18 04:46PM  Charles River Laboratories to Present at Evercore ISI Investor Conference Business Wire
Nov-20-18 06:22AM  Employees allege racial discrimination at Charles River Laboratories facility American City Business Journals
Nov-13-18 08:00AM  Charles River Laboratories Continues Commitment to Oncology Drug Discovery Business Wire
Nov-10-18 01:46PM  Edited Transcript of CRL earnings conference call or presentation 7-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-07-18 06:51PM  Charles River Laboratories International Inc (CRL) Q3 2018 Earnings Conference Call Transcript Motley Fool +8.86%
02:27PM  Charles River Laboratories International Inc (NYSE:CRL): Will The Growth Last? Simply Wall St.
08:25AM  Charles River Laboratories (CRL) Q3 Earnings and Revenues Top Estimates Zacks
07:21AM  Charles River: 3Q Earnings Snapshot Associated Press
07:00AM  Charles River Laboratories Announces Third-Quarter 2018 Results Business Wire
Oct-30-18 08:00AM  Charles River to Present Collaborative Methods at Neuroscience 2018 Business Wire
Oct-29-18 08:25AM  Market Trends Toward New Normal in Polaris Industries, NIKE, Charles River Laboratories International, Actuant, Caesarstone, and Enzo Biochem Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-25-18 08:00AM  Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform Business Wire
Oct-16-18 08:00AM  Charles River Laboratories Awarded Five-Year, $95.7 Million Contract by the National Institute of Allergy and Infectious Diseases Business Wire
Oct-10-18 04:30PM  Charles River Laboratories Schedules Third-Quarter 2018 Earnings Release and Conference Call Business Wire
Oct-02-18 04:53PM  Cancer center CEO leaves Merck board after disclosure scandal Reuters
Sep-18-18 10:42AM  Edited Transcript of CRL earnings conference call or presentation 8-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Sep-10-18 01:08PM  Why Charles River Laboratories International Incs (NYSE:CRL) ROE Of 10.8% Does Not Tell The Whole Story Simply Wall St.
Aug-30-18 04:37PM  Charles River Laboratories to Present at September Investor Conferences Business Wire
Aug-08-18 08:45AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Charles River Laboratories International, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors ACCESSWIRE
08:25AM  Charles River Laboratories (CRL) Beats Q2 Earnings and Revenue Estimates Zacks
07:16AM  Charles River: 2Q Earnings Snapshot Associated Press
07:00AM  Charles River Laboratories Announces Second-Quarter 2018 Results from Continuing Operations Business Wire
Aug-03-18 08:31AM  Can Tenet Healthcare (THC) Keep Earnings Beat Alive in Q2? Zacks
Aug-01-18 07:45AM  Research Report Identifies Myriad Genetics, Celldex Therapeutics, Charles River Laboratories International, Louisiana-Pacific, Integrated Device Technology, and Beazer Homes with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jul-11-18 04:33PM  Charles River Laboratories Schedules Second-Quarter 2018 Earnings Release and Conference Call Business Wire
Jun-21-18 12:41PM  A Look At The Fair Value Of Charles River Laboratories International Inc (NYSE:CRL) Simply Wall St.
Jun-15-18 09:23AM  Charles River Laboratories Is A Leader In Biopharma Outsourcing, KeyBanc Says In Upgrade Benzinga
Jun-04-18 04:30PM  Charles River Laboratories to Present at Jefferies and William Blair Conferences Business Wire
May-29-18 01:49PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Charles River Laboratories International, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
May-15-18 01:51AM  Edited Transcript of CRL earnings conference call or presentation 10-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-10-18 07:12AM  Charles River: 1Q Earnings Snapshot Associated Press
07:00AM  Charles River Laboratories Announces First-Quarter 2018 Results from Continuing Operations Business Wire
May-09-18 09:00AM  Should You Buy Charles River Laboratories (CRL) Before Earnings? Zacks
May-03-18 08:00AM  Charles River Laboratories Announces Extended Relationship with The Michael J. Fox Foundation Business Wire
May-01-18 08:00AM  Charles River Laboratories Expands Services for Early Discovery Screening Business Wire
Apr-12-18 04:30PM  Charles River Laboratories Schedules First-Quarter 2018 Earnings Release and Conference Call Business Wire
Apr-10-18 01:22PM  Edited Transcript of CRL presentation 7-Mar-17 6:05pm GMT Thomson Reuters StreetEvents
08:00AM  Charles River Laboratories Focuses on the Future of Oncology at AACR Annual Meeting 2018 Business Wire
Apr-09-18 08:00AM  Charles River Laboratories and PathoQuest Expand Strategic Biologics Partnership Business Wire
Apr-03-18 08:30AM  Charles River Laboratories Completes the Acquisition of MPI Research Business Wire
08:30AM  Charles River Laboratories Announces Closing of Senior Notes Offering Business Wire
Mar-26-18 10:20AM  Charles River Laboratories Int'l, Inc. -- Moody's assigns B1 to Charles River's unsecured notes; secured term loan upgraded to Ba1 Moody's
08:00AM  Charles River Laboratories Announces Refinancing of Credit Facilities and Offering of $500 Million of Senior Notes Business Wire
Mar-08-18 08:00AM  Charles River Laboratories Makes Expansions to Global Biologics Infrastructure Business Wire
Mar-05-18 08:00AM  Charles River Laboratories to Present at Raymond James and Barclays Conferences Business Wire
Mar-01-18 02:11PM  With A -20.00% Earnings Drop Lately, Did Charles River Laboratories International Inc (NYSE:CRL) Underperform Its Industry? Simply Wall St.
Feb-21-18 08:00AM  Charles River Laboratories Announces New Tumor Model Compendium Business Wire
Feb-16-18 07:40AM  Market Trends Toward New Normal in Tile Shop Holdings, Cytokinetics, Limelight Networks, CatchMark Timber Trust, Global Payments, and Charles River Laboratories International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-15-18 07:30AM  Wired News Charles River Labs Inked an Agreement to Acquire MPI Research ACCESSWIRE
Feb-13-18 07:08PM  Charles River Laboratories Int'l, Inc. -- Moody's affirms Charles River's Ba2 CFR; outlook stable Moody's +5.56%
05:47PM  Edited Transcript of CRL earnings conference call or presentation 13-Feb-18 1:30pm GMT Thomson Reuters StreetEvents
11:05AM  Charles River Labs to acquire contract research firm for $800M American City Business Journals
07:29AM  Charles River reports 4Q loss Associated Press
07:02AM  Charles River Laboratories Announces Executive Management Appointments Business Wire
07:01AM  Charles River Laboratories Announces Fourth-Quarter and Full-Year 2017 Results from Continuing Operations and Provides 2018 Guidance Business Wire
07:00AM  Charles River Laboratories to Acquire MPI Research Business Wire
Feb-09-18 08:55AM  Should You Buy Charles River Laboratories (CRL) Ahead of Earnings? Zacks
Feb-01-18 08:00AM  Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure Business Wire
Jan-25-18 04:30PM  Charles River Laboratories Schedules Fourth-Quarter 2017 Earnings and 2018 Guidance Release and Conference Call Business Wire
Jan-17-18 11:01AM  IIROC Trade Resumption - CRL, CRL.WT, CRL.RT PR Newswire
09:14AM  IIROC Trading Halt - CRL CRL.WT CRL.RT PR Newswire
Jan-16-18 08:00AM  Charles River Laboratories Adds Jean-Paul Mangeolle to Board of Directors Business Wire
Jan-15-18 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Jan-12-18 08:01AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Jan-11-18 07:00AM  Charles River Laboratories Acquires KWS BioTest Business Wire
Jan-09-18 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Jan-08-18 11:19AM  Carl Data Solutions Announces Completion of Rights Offering CNW Group
08:00AM  Charles River Laboratories to Present at J.P. Morgan Healthcare Conference Business Wire
Dec-26-17 07:50AM  Free Post Earnings Research Report: Charles Rivers Revenue Grew 9%; EPS Surged 36.7% ACCESSWIRE
Dec-21-17 07:05AM  Charles River Laboratories International, Inc. breached its 50 day moving average in a Bullish Manner : CRL-US : December 21, 2017 Capital Cube
Dec-13-17 03:00AM  Charles River Labs International Sees IBD RS Rating Rise To 72 Investor's Business Daily
Dec-11-17 01:44PM  ETFs with exposure to Charles River Laboratories International, Inc. : December 11, 2017 Capital Cube
Dec-08-17 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Dec-07-17 03:26PM  First Solar Flys Higher, Charles River Labs Flows In Reverse Forbes
Dec-06-17 08:00AM  Charles River Adds ERS License to CRISPR/Cas9 Service Offering Business Wire
Dec-01-17 10:34AM  ETFs with exposure to Charles River Laboratories International, Inc. : December 1, 2017 Capital Cube
08:00AM  Investor Expectations to Drive Momentum within CatchMark Timber Trust, Global Payments, Charles River Laboratories International, Tile Shop Hldgs, Cytokinetics, and Limelight Networks Discovering Underlying Factors of Influence GlobeNewswire
Nov-28-17 08:00AM  Charles River Announces Success of Integrated Discovery Project with ENYO Pharma Business Wire
Nov-20-17 12:04PM  ETFs with exposure to Charles River Laboratories International, Inc. : November 20, 2017 Capital Cube
Nov-17-17 08:06AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Nov-15-17 07:13PM  Cramer's lightning round: Don't buy Mallinckrodt after it... CNBC Videos
06:49PM  Cramer's lightning round: Sell Mallinckrodt after its 'nutty' acquisition of Acthar CNBC
09:36AM  Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q3, 2017 By the Numbers : November 15, 2017 Capital Cube
Nov-14-17 08:06AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
07:20AM  Earnings Review and Free Research Report: Labcorps Revenue Jumped 9.5%; Raised Outlook for 2017 ACCESSWIRE
Nov-13-17 01:57PM  Charles River Laboratories International, Inc. Value Analysis (NYSE:CRL) : November 13, 2017 Capital Cube
06:44AM  Edited Transcript of CRL earnings conference call or presentation 9-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-10-17 07:29AM  Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : November 10, 2017 Capital Cube
Nov-09-17 12:26PM  ETFs with exposure to Charles River Laboratories International, Inc. : November 9, 2017 Capital Cube -12.69%
11:45AM  What Should You Know About Charles River Laboratories International Incs (CRL) Future? Simply Wall St.
07:15AM  Charles River tops Street 3Q forecasts Associated Press
07:00AM  Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations Business Wire
Nov-08-17 08:50AM  Why Earnings Season Could Be Great for Charles River Laboratories (CRL) Zacks
Nov-01-17 08:00AM  Charles River Laboratories Presents Newly Expanded Capabilities at Neuroscience 2017 Business Wire
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves pharmaceutical and biotechnology, agricultural and chemical, life science and veterinary medicine, and medical device companies; and contract research and contract manufacturing organizations, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOSTER JAMES CChairman, President and CEODec 10Option Exercise73.7025,1231,851,565310,894Dec 12 12:09 PM
FOSTER JAMES CChairman, President and CEODec 10Sale129.111,977255,252285,771Dec 12 12:19 PM
FOSTER JAMES CChairman, President and CEODec 10Sale127.473,668467,555291,416Dec 12 12:17 PM
FOSTER JAMES CChairman, President and CEODec 10Sale126.733,981504,523299,204Dec 12 12:16 PM
FOSTER JAMES CChairman, President and CEODec 10Sale126.414,308544,567303,185Dec 12 12:14 PM
FOSTER JAMES CChairman, President and CEODec 10Sale128.253,668470,416287,748Dec 12 12:12 PM
FOSTER JAMES CChairman, President and CEODec 10Sale127.104,120523,650295,084Dec 12 12:11 PM
FOSTER JAMES CChairman, President and CEODec 10Sale126.053,401428,690307,493Dec 12 12:09 PM
BERTOLINI ROBERT JDirectorDec 04Option Exercise33.934,540154,04229,876Dec 06 08:30 AM
BERTOLINI ROBERT JDirectorDec 04Sale134.711,100148,17925,336Dec 06 08:31 AM
BERTOLINI ROBERT JDirectorDec 04Sale133.773,440460,15426,436Dec 06 08:30 AM
Smith David RossCorporate Executive VP & CFONov 12Sale134.491,866250,96110,575Nov 14 10:53 AM
JOHST DAVID PCorporate Executive VPNov 07Option Exercise59.4123,3561,387,580219,849Nov 08 01:29 PM
JOHST DAVID PCorporate Executive VPNov 07Sale136.0023,3563,176,416196,493Nov 08 01:29 PM
Kochevar Deborah TurnerDirectorSep 04Sale123.664,066502,7996,424Sep 05 03:28 PM
Smith David RossCorporate Executive VP & CFOAug 13Option Exercise76.121,24995,07413,690Aug 14 01:34 PM
Smith David RossCorporate Executive VP & CFOAug 13Sale120.051,249149,94812,441Aug 14 01:34 PM
Molho DavidePresident & COOJul 24Option Exercise68.0513,849942,44835,928Jul 25 06:45 PM
Molho DavidePresident & COOJul 24Sale125.0018,7732,346,62517,155Jul 25 06:45 PM
Molho DavidePresident & COOJul 23Sale125.0011,6001,450,00022,079Jul 24 06:36 PM
Molho DavidePresident & COOJul 17Option Exercise76.676,165472,67144,805Jul 19 08:37 AM
Molho DavidePresident & COOJul 17Sale120.0011,1261,335,12033,679Jul 19 08:37 AM
Girshick BirgitCorporate Executive VPJul 17Sale119.903,978476,96218,999Jul 18 02:32 PM
FOSTER JAMES CChairman & CEOJul 02Sale111.552,775309,540271,676Jul 05 11:29 AM
FOSTER JAMES CChairman & CEOJul 02Sale111.345,348595,462274,451Jul 05 11:28 AM
FOSTER JAMES CChairman & CEOJul 02Sale111.115,471607,865279,799Jul 05 11:24 AM
FOSTER JAMES CChairman & CEOJul 02Sale110.805,005554,552285,270Jul 05 11:22 AM
FOSTER JAMES CChairman & CEOJul 02Sale110.536,401707,472290,275Jul 05 11:00 AM
MASSARO GEORGEDirectorJun 25Option Exercise52.293,530184,58417,367Jun 26 03:14 PM
MASSARO GEORGEDirectorJun 25Sale115.5530034,66513,837Jun 26 03:18 PM
MASSARO GEORGEDirectorJun 25Sale114.053,230368,38114,137Jun 26 03:14 PM
MASSARO GEORGEDirectorMay 14Sale107.191,218130,55813,837May 15 04:09 PM
Smith David RossCorporate Executive VP & CFOMay 01Option Exercise51.4594548,62013,723May 03 08:44 AM
Smith David RossCorporate Executive VP & CFOMay 01Sale104.2394598,49912,778May 03 08:44 AM
MILNE GEORGE M JRDirectorMar 09Option Exercise40.277,740311,69036,760Mar 13 11:43 AM
MILNE GEORGE M JRDirectorMar 09Sale115.007,740890,10029,020Mar 13 11:43 AM
Girshick BirgitCorporate Executive VPMar 06Option Exercise79.277,313579,69432,870Mar 07 04:52 PM
FOSTER JAMES CChairman & CEOMar 06Option Exercise88.0524,0082,113,904325,684Mar 07 04:56 PM
FOSTER JAMES CChairman & CEOMar 06Sale110.0024,0082,640,880301,676Mar 07 04:56 PM
Girshick BirgitCorporate Executive VPMar 06Sale109.109,8931,079,34322,977Mar 07 04:52 PM
Smith David RossCorporate Executive VP & CFOFeb 28Option Exercise88.054,365384,33818,443Mar 02 11:04 AM
FOSTER JAMES CChairman & CEOFeb 28Option Exercise59.4120,0721,192,478324,012Mar 02 07:25 AM
Smith David RossCorporate Executive VP & CFOFeb 28Sale108.4310010,84313,103Mar 02 11:06 AM
Smith David RossCorporate Executive VP & CFOFeb 28Sale107.905,240565,41413,203Mar 02 11:04 AM
FOSTER JAMES CChairman & CEOFeb 28Sale108.472,102227,995303,940Mar 02 07:34 AM
FOSTER JAMES CChairman & CEOFeb 28Sale108.244,398476,046306,042Mar 02 07:32 AM
FOSTER JAMES CChairman & CEOFeb 28Sale108.035,102551,176310,440Mar 02 07:30 AM
FOSTER JAMES CChairman & CEOFeb 28Sale107.815,098549,639315,542Mar 02 07:28 AM
FOSTER JAMES CChairman & CEOFeb 28Sale107.393,372362,113320,640Mar 02 07:25 AM
Smith David RossCorporate Executive VP & CFOFeb 27Option Exercise76.672,158165,45416,236Mar 01 12:50 PM
FOSTER JAMES CChairman & CEOFeb 27Option Exercise76.7021,5771,654,956325,517Mar 01 12:11 PM
Smith David RossCorporate Executive VP & CFOFeb 27Sale108.102,158233,28314,078Mar 01 12:50 PM
FOSTER JAMES CChairman & CEOFeb 27Sale108.414,707510,282303,940Mar 01 12:39 PM
FOSTER JAMES CChairman & CEOFeb 27Sale108.157,067764,280308,647Mar 01 12:35 PM
FOSTER JAMES CChairman & CEOFeb 27Sale107.915,993646,703315,714Mar 01 12:15 PM
FOSTER JAMES CChairman & CEOFeb 27Sale107.663,810410,199321,707Mar 01 12:11 PM
FOSTER JAMES CChairman & CEOFeb 26Option Exercise73.7025,1241,851,639331,238Feb 28 03:12 PM
Smith David RossCorporate Executive VP & CFOFeb 26Option Exercise73.704,187308,58218,483Feb 28 07:12 AM
Smith David RossCorporate Executive VP & CFOFeb 26Sale108.5331934,62014,296Feb 28 07:16 AM
Smith David RossCorporate Executive VP & CFOFeb 26Sale107.353,868415,22414,615Feb 28 07:12 AM
FOSTER JAMES CChairman & CEOFeb 26Sale108.8190097,929306,114Feb 28 03:40 PM
FOSTER JAMES CChairman & CEOFeb 26Sale108.434,429480,232307,014Feb 28 03:39 PM
FOSTER JAMES CChairman & CEOFeb 26Sale107.855,269568,287311,443Feb 28 03:30 PM
FOSTER JAMES CChairman & CEOFeb 26Sale107.313,999429,135316,712Feb 28 03:25 PM
FOSTER JAMES CChairman & CEOFeb 26Sale107.005,727612,779320,711Feb 28 03:15 PM
FOSTER JAMES CChairman & CEOFeb 26Sale106.694,800512,123326,438Feb 28 03:12 PM
Barbo William DCorporate Executive VP & CCOFeb 21Sale108.082,320250,74119,156Feb 22 11:14 AM
Smith David RossCorporate Executive VP & CFOFeb 16Sale109.073,639396,89911,671Feb 20 02:45 PM
CHUBB STEPHEN DDirectorFeb 15Option Exercise40.277,740311,69036,461Feb 16 08:30 AM
CHUBB STEPHEN DDirectorFeb 15Sale108.702,872312,17233,589Feb 16 08:30 AM
FOSTER JAMES CChairman, President and CEOFeb 15Sale107.50464,94529,954Feb 20 02:38 PM
Smith David RossCorporate Executive VP & CFOJan 02Option Exercise51.4516,817865,23528,488Jan 03 03:52 PM
BERTOLINI ROBERT JDirectorJan 02Option Exercise40.277,740311,69030,326Jan 03 04:11 PM
BERTOLINI ROBERT JDirectorJan 02Sale110.223,609397,78522,586Jan 03 04:14 PM
BERTOLINI ROBERT JDirectorJan 02Sale109.594,131452,71726,195Jan 03 04:11 PM
Smith David RossCorporate Executive VP & CFOJan 02Sale110.383,100342,19111,671Jan 03 03:56 PM
Smith David RossCorporate Executive VP & CFOJan 02Sale110.018,231905,49714,771Jan 03 03:54 PM
Smith David RossCorporate Executive VP & CFOJan 02Sale109.535,486600,89123,002Jan 03 03:52 PM
FOSTER JAMES CChairman, President and CEOJan 02Sale110.313,465382,229295,266Jan 04 11:17 AM
FOSTER JAMES CChairman, President and CEOJan 02Sale110.169,2461,018,558298,731Jan 04 11:15 AM
FOSTER JAMES CChairman, President and CEOJan 02Sale109.787,322803,823307,977Jan 04 11:12 AM
FOSTER JAMES CChairman, President and CEOJan 02Sale109.444,967543,590315,299Jan 04 11:09 AM